BEVERLY, MA--(Marketwire - May 9, 2011) - Cellceutix Corporation (
Leo Ehrlich, CEO of Cellceutix, stated, "I would like to congratulate the Cellceutix team including our many consultants, shareholders, and vendors on this important event. Yes, many thought it was impossible to accomplish what we have achieved. Not only have we have created a new chemical class and breakthrough in medicine; we completed this at amazing speed, about three years, and expect shortly to file our IND. We are working diligently to see Cellceutix flourish and believe the best is yet to come."
About Cellceutix
Cellceutix Corporation is a preclinical cancer, anti-inflammatory and autism drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for certain cancers, KM-133, for the treatment of psoriasis, and KM-391, for the treatment of autism. More information is available on the Cellceutix web site at